Last reviewed · How we verify
NCT04565327
Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma
Phase 2 trial testing Hyperpolarized Carbon C 13 Pyruvate in Pancreatic Ductal Adenocarcinoma in 7 participants. Terminated before completion.
1 November 2022
Quick facts
| Lead sponsor | Zhen Wang, MD |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 7 |
| Start date | 14 August 2020 |
| Primary completion | 1 November 2022 |
| Estimated completion | 1 November 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Hyperpolarized Carbon C 13 Pyruvate — full drug profile →
- Magnetic Resonance Imaging (MRI)
Conditions studied
- Pancreatic Ductal Adenocarcinoma — all drugs for Pancreatic Ductal Adenocarcinoma →
Sponsor
Zhen Wang, MD
Who can join
18 and older, any sex, with Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial investigates whether magnetic resonance imaging (MRI) using hyperpolarized carbon-13 (13C) pyruvate can be useful for evaluating early treatment response in patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) or spread to other places in the body (metastatic). Hyperpolarized 13C pyruvate is different from standard clinical MRI contrast (e.g. gadolinium) in that it provides information on how a tumor processes nutrients. MRI is used to see tumor uptake and breakdown of hyperpolarized carbon-13 pyruvate molecules, which can tell how the tumor processes nutrients. Hyperpolarized 13C pyruvate MRI may help in understanding how the tumor responds to the treatments patients may be receiving.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Comprehensive Literature Review of Hyperpolarized Carbon-13 MRI: The Road to Clinical Application.
Vaeggemose M, F Schulte R, Laustsen C. · · 2021 · cited 35× · PMID 33916803 · DOI 10.3390/metabo11040219 -
Metabolic response to radiation therapy in cancer.
Read GH, Bailleul J, Vlashi E, Kesarwala AH. · · 2022 · cited 25× · PMID 34961986 · DOI 10.1002/mc.23379 -
Hyperpolarized <sup>13</sup>C Metabolic MRI of Patients with Pancreatic Ductal Adenocarcinoma.
Gordon JW, Chen HY, Nickles T, Lee PM, et al · · 2024 · cited 15× · PMID 38041836 · DOI 10.1002/jmri.29162 -
Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma.
Ali A, Chianese U, Papulino C, Toraldo A, et al · · 2022 · cited 8× · PMID 35954462 · DOI 10.3390/cancers14153799
Verify or expand the search:
- PubMed search for NCT04565327
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hyperpolarized Carbon C 13 Pyruvate
Trials testing the same drug.
- NCT04589624 — An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies · Phase 1 · recruiting
- NCT04286386 — Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam · active not recruiting
- NCT03830151 — Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors · Phase 1 · recruiting
- NCT03581500 — Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patient · Phase 2 · withdrawn
- NCT04258462 — Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors · Phase 2 · active not recruiting
Other recruiting trials for Pancreatic Ductal Adenocarcinoma
Currently open trials in the same condition.
- NCT07324096 — A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Deve · NA · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07328607 — Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy · NA · recruiting
- NCT07232810 — Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer · NA · recruiting
- NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
Other Zhen Wang, MD trials
Trials by the same sponsor.
- NCT04258462 — Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04565327 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhen Wang, MD
- Last refreshed: 13 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04565327.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing